+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Head and Neck Cancer Therapeutics Market Report and Forecast 2023-2031

  • PDF Icon

    Report

  • 140 Pages
  • July 2023
  • Region: Global
  • Expert Market Research
  • ID: 5855081
The global head and neck cancer therapeutics market was valued at USD 1.5 billion in 2022, driven by the increasing prevalence of increasing incidence of head and neck cancer across the globe. The market size is anticipated to grow at a CAGR of 11.17% during the forecast period of 2023-2031 to achieve a value of USD 3.9 billion by 2031.

Head and Neck Cancer Therapeutics: Introduction

Head and neck cancer refers to a group of cancers that occur in the head and neck region, including the oral cavity, throat, larynx, and sinuses. The treatment of head and neck cancer involves a multimodal approach, which may include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. The goal of head and neck cancer therapeutics is to effectively control and treat the disease, improve patient outcomes, and preserve or restore the function and quality of life for individuals affected by this condition.

Key Trends in the Head and Neck Cancer Therapeutics Market

Some key trends involved in the head and neck cancer therapeutics market are as follows:
  • Advancements in Targeted Therapies: Targeted therapies have revolutionized the treatment landscape for head and neck cancer. These therapies specifically target certain molecules or pathways involved in the growth and progression of cancer cells, resulting in more precise and effective treatment options. Key targeted therapies for head and neck cancer include EGFR inhibitors, immune checkpoint inhibitors, and angiogenesis inhibitors
  • Immunotherapy Breakthroughs: Immunotherapy has emerged as a promising approach in the treatment of head and neck cancer. Immune checkpoint inhibitors, such as PD-1 and PD-L1 inhibitors, have shown significant efficacy in improving overall survival and response rates in certain patient populations. The use of immunotherapy in combination with other treatment modalities is being explored to enhance treatment outcomes
  • Personalized Medicine: The field of personalized medicine is gaining momentum in head and neck cancer therapeutics. Advances in molecular profiling and genomic testing enable healthcare professionals to identify specific genetic mutations or alterations in tumors. This information helps in selecting targeted therapies or immunotherapies that are most likely to be effective for individual patients, leading to improved treatment outcomes and reduced side effects

Head and Neck Cancer Therapeutics Market Segmentations

Market Breakup by Therapy Type

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Radiation Therapy

Market Breakup by Route of Administration

  • Oral
  • Parenteral

Market Breakup by Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Pharmacies

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Head and Neck Cancer Therapeutics Market Scenario

The market for head and neck cancer therapeutics is a dynamic and rapidly evolving segment within the broader oncology market. Head and neck cancer is a significant healthcare challenge, with a high prevalence worldwide. The market is driven by the increasing incidence of head and neck cancer, advancements in treatment options, and a growing focus on personalized medicine and patient-centric care.

The global market for head and neck cancer therapeutics is characterized by the presence of several key players, including pharmaceutical companies, biotechnology firms, and medical device manufacturers. These companies are actively involved in research and development activities to develop innovative therapies and treatment approaches for head and neck cancer.

Overall, the market for head and neck cancer therapeutics is characterized by innovation, advancements in personalized medicine, a shift towards targeted therapies and immunotherapies, and a focus on minimally invasive surgical techniques. These key factors are driving the market and shaping the future of head and neck cancer treatment, with the ultimate goal of improving patient outcomes and enhancing the quality of life for individuals affected by this disease.

Head and Neck Cancer Therapeutics Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • AstraZeneca Plc
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
  • Fresenius Medical Care AG & Co. KGaA,
  • Merck & Co., Inc
  • Pfizer Inc
  • Sanofi
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Limited
*The publisher always strives to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Head and Neck Cancer Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Head and Neck Cancer Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Head and Neck Cancer Epidemiology (2016-2031)
5.3 Europe Head and Neck Cancer Epidemiology (2016-2031)
5.4 Asia-Pacific Head and Neck Cancer Epidemiology (2016-2031)
5.5 Latin America Head and Neck Cancer Epidemiology (2016-2031)
5.6 Middle East & Africa Head and Neck Cancer Epidemiology (2016-2031)
6 Global Head and Neck Cancer Therapeutics Market Overview
6.1 Global Head and Neck Cancer Therapeutics Market Historical Value (2016-2022)
6.2 Global Head and Neck Cancer Therapeutics Market Forecast Value (2023-2031)
7 Head and Neck Cancer Therapeutics Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Cost of Treatment
9 Global Head and Neck Cancer Therapeutics Market Dynamics
9.1 Market Drivers and Constraints
9.2 SWOT Analysis
9.3 Porter’s Five Forces Model
9.4 Key Demand Indicators
9.5 Key Price Indicators
9.6 Industry Events, Initiatives, and Trends
9.7 Value Chain Analysis
10 Global Head and Neck Cancer Therapeutics Market Segmentation
10.1 Global Head and Neck Cancer Therapeutics Market by Therapy Type
10.1.1 Market Overview
10.1.2 Chemotherapy
10.1.3 Immunotherapy
10.1.4 Targeted Therapy
10.1.5 Radiation Therapy
10.2 Global Head and Neck Cancer Therapeutics Market by Route of Administration
10.2.1 Market Overview
10.2.2 Oral
10.2.3 Parenteral
10.3 Global Head and Neck Cancer Therapeutics Market by Distribution Channel
10.3.1 Market Overview
10.3.2 Hospital Pharmacies
10.3.3 Drug Stores & Retail Pharmacies
10.3.4 Online Pharmacies
10.4 Global Head and Neck Cancer Therapeutics Market by Region
10.4.1 Market Overview
10.4.2 North America
10.4.3 Europe
10.4.4 Asia Pacific
10.4.5 Latin America
10.4.6 Middle East and Africa
11 North America Head and Neck Cancer Therapeutics Market
11.1 Market Share by Country
11.2 United States of America
11.3 Canada
12 Europe Head and Neck Cancer Therapeutics Market
12.1 Market Share by Country
12.2 United Kingdom
12.3 Germany
12.4 France
12.5 Italy
12.6 Others
13 Asia Pacific Head and Neck Cancer Therapeutics Market
13.1 Market Share by Country
13.2 China
13.3 Japan
13.4 India
13.5 ASEAN
13.6 Australia
13.7 Others
14 Latin America Head and Neck Cancer Therapeutics Market
14.1 Market Share by Country
14.2 Brazil
14.3 Argentina
14.4 Mexico
14.5 Others
15 Middle East and Africa Head and Neck Cancer Therapeutics Market
15.1 Market Share by Country
15.2 Saudi Arabia
15.3 United Arab Emirates
15.4 Nigeria
15.5 South Africa
15.6 Others
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 AstraZeneca Plc.
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisitions
22.1.5 Certifications
22.2 Bristol-Myers Squibb Company
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 Eli Lilly and Company
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 Fresenius Medical Care AG & Co. KGaA,
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 Merck & Co., Inc.
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 Pfizer Inc.
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 Sanofi
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 Sun Pharmaceutical Industries Ltd.
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 Teva Pharmaceutical Industries Limited
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
23 Head and Neck Cancer Therapeutics - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
  • *Additional insights provided are customisable as per client requirements.

Companies Mentioned

  • AstraZeneca Plc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
  • Fresenius Medical Care AG & Co. KGaA
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Limited

Methodology

Loading
LOADING...

Table Information